Literature DB >> 1455086

Applications and limitations of vitreoretinal biopsy techniques in intraocular large cell lymphoma.

M S Blumenkranz1, T Ward, S Murphy, W Mieler, G A Williams, J Long.   

Abstract

The cases of 4 patients with clinical signs of intraocular large cell lymphoma are described. Initial cytopathologic examination of vitrectomy specimens failed to establish the malignant character of the vitreous infiltrates. Three of the four patients eventually developed solid central nervous system tumors, intracranial biopsy samples of which revealed large cell lymphoma, 13 months to 42 months after initial examination. In one patient, transscleral retinochoroidal biopsy confirmed the diagnosis at the same time as negative vitreous cytologic examination. Results of cytopathologic examination alone of vitreous biopsy specimens may not be sufficient to make a diagnosis in certain cases of large cell lymphoma that are subsequently documented by CNS biopsy. Careful attention should be paid to the handling, processing, and interpretation of vitrectomy specimens from patients suspected of having intraocular large cell lymphoma. Consideration should be given to immunocytologic staining and interpretation by centers that are highly experienced in vitreous cytopathology.

Entities:  

Mesh:

Year:  1992        PMID: 1455086     DOI: 10.1097/00006982-199212031-00014

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  Protocol for the use of polymerase chain reaction in the detection of intraocular large B-cell lymphoma in ocular samples.

Authors:  Aires Lobo; Narciss Okhravi; Peter Adamson; Brian J Clark; Susan Lightman
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

2.  Anterior chamber paracentesis cytology (cytospin technique) for the diagnosis of intraocular lymphoma.

Authors:  P T Finger; C Papp; P Latkany; M Kurli; C E Iacob
Journal:  Br J Ophthalmol       Date:  2006-02-17       Impact factor: 4.638

3.  Diagnostic cellular yield is superior with full pars plana vitrectomy compared with core vitreous biopsy.

Authors:  H S Mudhar; R Sheard
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

Review 4.  Primary intraocular lymphoma of T-cell type: report of a case and review of the literature.

Authors:  Sarah E Coupland; Gerasimos Anastassiou; Norbert Bornfeld; Michael Hummel; Harald Stein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-10       Impact factor: 3.117

5.  Assessment of HOPE fixation in vitrectomy specimens in patients with chronic bilateral uveitis (masquerade syndrome).

Authors:  Sarah E Coupland; Alexandra Perez-Canto; Michael Hummel; Harald Stein; Heinrich Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-21       Impact factor: 3.117

6.  Diagnosis of intraocular lymphoma by polymerase chain reaction.

Authors:  N Katai; S Kuroiwa; K Fujimori; N Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-07       Impact factor: 3.117

Review 7.  Intraocular lymphoma: update on diagnosis and management.

Authors:  Chi-Chao Chan; Dana J Wallace
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

8.  Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome.

Authors:  Sarah E Coupland; Nikolaos E Bechrakis; Gerasimos Anastassiou; Andreas M H Foerster; Arnd Heiligenhaus; Uwe Pleyer; Michael Hummel; Harald Stein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-09-30       Impact factor: 3.117

Review 9.  Biopsy techniques and yields in diagnosing primary intraocular lymphoma.

Authors:  John A Gonzales; Chi-Chao Chan
Journal:  Int Ophthalmol       Date:  2007-04-18       Impact factor: 2.031

Review 10.  Vitreous diagnosis in neoplastic diseases.

Authors:  Mónica Asencio-Duran; José Luis Vallejo-Garcia; Natalia Pastora-Salvador; Agustín Fonseca-Sandomingo; Mario R Romano
Journal:  Mediators Inflamm       Date:  2012-09-26       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.